Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123339 | 0.90 | POLB (0.43) | POLBSMN1; SMN2SCN9AHPGDSHRH3 | |
| SCHEMBL7122583 | 0.90 | POLB (0.50) | POLBSMN1; SMN2SCN9AHPGDSHRH3 | |
| SCHEMBL7126711 | 0.88 | HRH3 (0.47) | POLBSMN1; SMN2SCN9AHRH3PRKAA2 | |
| SCHEMBL7125155 | 0.88 | POLB (0.41) | POLBSMN1; SMN2SCN9AHPGDSHRH3 | |
| SCHEMBL7116944 | 0.87 | HPGD (0.46) | SMN1; SMN2MMP2MMP7MMP9MMP13 | |
| SCHEMBL7125270 | 0.86 | LOXL2 (0.38) | POLBSCN9AMMP2MMP7MMP9 | |
| SCHEMBL7117106 | 0.86 | SCN9A (0.56) | SCN9ALMNALIPE | |
| SCHEMBL7116059 | 0.86 | POLB (0.39) | POLBSMN1; SMN2SCN9ALMNAMMP2 | |
| SCHEMBL7121263 | 0.85 | EPHX2 (0.42) | POLBSMN1; SMN2SCN9APRKAA2 | |
| SCHEMBL7116208 | 0.84 | POLB (0.36) | POLBSMN1; SMN2SCN9AMMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | POLB 767/4885SMN1; SMN2 1918/4885SCN9A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.